title: Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
abstract: BACKGROUND
  Insulin resistance is a key feature of type 2 diabetes mellitus. Plasma cell differentiation antigen (PC-1) is an inhibitor of insulin receptor tyrosine kinase, and has been implicated in the pathogenesis of insulin resistance.
  
  
  METHODS
  Urinary excretion of PC-1 was determined in 45 newly detected, obese diabetic patients treated with metformin (16 patients), gliclazide (14 patients) or glibenclamide (15 patients). Urinary N-acetyl-beta-D-glucosaminidase (NAGA), a lysosomal enzyme, was determined as a marker of tubular damage in diabetes.
  
  
  RESULTS
  Basal urinary PC-1 excretion in all three groups of diabetic patients was at the level of healthy controls. Treatment with oral hypoglycaemic drugs did not change significantly the group level or the number of patients in each group with increased PC-1 activity. Urinary excretion of NAGA in patients with type 2 diabetes was not statistically different from the control level. Metformin and gliclazide treatment did not change significantly the group levels of NAGA excretion. However, glibenclamide treatment produced an increased urinary NAGA excretion in the whole group, and in about twice as many patients as in the pre-treatment period.
authors.affiliation: Institute of Nephrology and Hemodialysis, B. Tasković 48, 18000 Nis, Serbia. stefan@ni.acc.yu
authors.forename: V
authors.initials: V
authors.lastname: Stefanović
authors.forename: S
authors.initials: S
authors.lastname: Antić
authors.forename: M
authors.initials: M
authors.lastname: Mitić-Zlatković
authors.forename: S
authors.initials: S
authors.lastname: Stojiljković
authors.forename: M
authors.initials: M
authors.lastname: Milojković
authors.forename: M
authors.initials: M
authors.lastname: Bogicević
authors.forename: P
authors.initials: P
authors.lastname: Vlahović
mesh_terms: D000118:Acetylglucosaminidase / Q000097:blood* / Q000652:urine*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003404:Creatinine / Q000097:blood / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity; D010727:Phosphoric Diester Hydrolases / Q000097:blood* / Q000652:urine*; D011755:Pyrophosphatases / Q000097:blood* / Q000652:urine*
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin; D003404:Creatinine; D010727:Phosphoric Diester Hydrolases; C065962:ectonucleotide pyrophosphatase phosphodiesterase 1; D000118:Acetylglucosaminidase; D011755:Pyrophosphatases; D005907:Gliclazide; D005905:Glyburide